Since circulating MET ectodomain shedding is also reported in preclinical cancer cell models and lung cancer patients [49, 50], how soluble MET shedding would influence MET-CAR-T cell efficacy needs to be evaluated when MET-CAR-T cells enter clinical trials. This evidence concerns the gene MET and lung cancer.